News & Insights

Facility Spotlight: Winnipeg, Manitoba, Canada

Written by Emergent CDMO | Jan 18, 2023 3:57:10 PM

For more than 30 years, our Winnipeg, Manitoba (Canada) site has offered a broad range of expertise for drug substance and drug product manufacturing. The 150,000-sq.ft. facility manufactures polyclonal hyperimmune products, plasma therapeutics, lipoproteins, and mRNA products, and houses a SA25 aseptic filling workcell — a gloveless, robotic isolator ideal for high-value biologic products.


Learn more about how our Winnipeg site is equipped to support your next clinical or commercial drug candidate.